{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for penicillin root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT00932100: Phase 2 Interventional Completed Acute Coronary Syndrome (ACS)
(2009)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT04544956: Phase 2 Interventional Completed Hepatitis B
(2020)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00002403: Phase 1 Interventional Completed HIV Infections
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT01065935: Phase 2 Interventional Completed Respiratory Syncytial Virus Infections
(2010)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00306904: Phase 2 Interventional Completed Diabetic Macular Edema
(2006)
Source URL:
Class:
NUCLEIC ACID
Status:
Investigational
Source:
NCT00042081: Phase 3 Interventional Completed Coronary Artery Disease
(2002)
Source URL:
Class:
NUCLEIC ACID
Status:
Designated
Source:
FDA ORPHAN DRUG:173903
Source URL:
Class:
NUCLEIC ACID
Status:
US Previously Marketed
Source:
KYNAMRO by KASTLE THERAPS LLC
(2013)
Source URL:
First approved in 2013
Source:
KYNAMRO by KASTLE THERAPS LLC
Source URL:
Class:
NUCLEIC ACID
Status:
US Previously Marketed
Source:
VITRAVENE PRESERVATIVE FREE by NOVARTIS
(1998)
Source URL:
First approved in 1998
Source:
VITRAVENE PRESERVATIVE FREE by NOVARTIS
Source URL:
Class:
NUCLEIC ACID